1639P Integrated safety analysis of tazemetostat (TAZ) 800 mg BID in adult patients (pts) with hematologic and solid tumors

Authors :: George D. Demetri
Marjorie G. Zauderer
Mrinal M. Gounder
Hervé Tilly
P. Slatcher
Dean A. Fennell
Victor M. Villalobos
Jay Yang
Gregory M. Cote
Gilles Salles
Aristeidis Chaidos
L. Sierra
Patrick Schöffski
Shefali Agarwal
Robin L. Jones
Tycel Phillips
Franck Morschhauser
Gary K. Schwartz
Pamela McKay
Silvia Stacchiotti
Source :: Annals of Oncology. 31:S981-S982
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
medicine.medical_specialty
Adult patients
Tazemetostat
business.industry
Internal medicine
medicine
Hematology
business

Full Text Access

Tools